Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.